Search results for "Infectious"

showing 10 items of 2953 documents

Efficacy of protection by latex gloves during orthodontic therapy.

2000

The wearing of gloves during orthodontic or dental treatment is generally indicated for reasons of hygiene and protection against infection. This study was aimed at determining the extent and localization of perforations caused by the various orthodontic treatment techniques and interrupting the infection barrier. The impermeability was tested by means of a water retention test according to European standard EN 455, Part 1, performed on 1600 Centramed (Centramed, Koblenz), Tekmedic and SafeEx non-sterile disposable latex gloves (both by Safe Med, Switzerland) and Safe Gan latex gloves with an additional acrylate coating (also by Safe Med). The perforation rate in unused gloves was between 0…

medicine.medical_specialtyChi-Square DistributionInfectious Disease Transmission Patient-to-ProfessionalLatexbusiness.industrymedia_common.quotation_subjectInfection Control DentalDentistryOrthodonticsPermeabilitySurgeryInfectious Disease Transmission Professional-to-PatientEquipment Failure AnalysisHygieneProtective glovesEvaluation Studies as TopicOral and maxillofacial surgeryMedicineHumansOral SurgerybusinessGloves Protectivemedia_commonJournal of orofacial orthopedics = Fortschritte der Kieferorthopadie : Organ/official journal Deutsche Gesellschaft fur Kieferorthopadie
researchProduct

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cir…

2012

Summary.  Genetic factors can influence the outcome of antiviral therapy in chronic hepatitis C (HCV). We evaluated the role of interleukin-28B single nucleotide polymorphisms (SNPs) and inosine triphosphatase (ITPA) gene variants in HCV cirrhosis treated with Peg-Interferon and ribavirin. A prospective cohort of 233 patients with compensated cirrhosis received 1–1.5 μg/kg/week of Peg-Interferon alpha-2b plus 1000–1200 mg/day of RBV for 48 weeks. A sustained virologic response (SVR) was achieved in 27% of patients. On multivariate logistic analysis, the absence of oesophageal varices (OR 3.64 CI 95% 1.27–10.44 P = 0.016), infection with genotype 2 or 3 (OR 4.06, CI 95% 1.08–15.26, P = 0.038…

medicine.medical_specialtyCirrhosisHepatologyCombination therapybusiness.industryRibavirinmedicine.diseaseGastroenterologychemistry.chemical_compoundInfectious DiseaseschemistryVirologyInternal medicineImmunologymedicinePortal hypertensionITPAVaricesRapid Virologic ResponsebusinessProspective cohort studyJournal of Viral Hepatitis
researchProduct

Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe

2018

Abstract: Hepatitis C virus (HCV) infection is a major public health problem in the European Union (EU). An estimated 5.6 million Europeans are chronically infected with a wide range of variation in prevalence across European Union countries. Although HCV continues to spread as a largely silent pandemic, its elimination is made possible through the availability of the new antiviral drugs and the implementation of prevention practices. On 17 February 2016, the Hepatitis B & C Public Policy Association held the first EU HCV Policy Summit in Brussels. This summit was an historic event as it was the first high-level conference focusing on the elimination of HCV at the European Union level. The …

medicine.medical_specialtyCivil societyEconomic growthMedizinPublic policyHepacivirusAntiviral AgentsPatient advocacy03 medical and health sciences0302 clinical medicineVirologyPolitical sciencePandemicPrevalencemedicineHumansmedia_common.cataloged_instanceEuropean Union030212 general & internal medicineDisease EradicationEuropean unionmedia_commongeographySummitgeography.geographical_feature_categoryHepatologyPublic healthmedicine.diseaseHepatitis CEuropeInfectious DiseasesHCVEpidemiological Monitoring030211 gastroenterology & hepatologyHuman medicineViral hepatitisJournal of Viral Hepatitis
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the …

2018

Summary Cytomegalovirus is one of the most important infections to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen in patients treated with recently introduced drugs for hematological malignancies. Expert recommendations have been produced by the 2017 European Conference on Infections in Leukaemia (ECIL 7) after a review of the literature on the diagnosis and management of cytomegalovirus in patients after HSCT and in patients receiving other types of therapy for haematological malignancies. These recommendations cover diagnosis, preventive strategies such as pr…

medicine.medical_specialtyCongenital cytomegalovirus infectionCytomegalovirusAntiviral AgentsLetermovirInternal medicinemedicineHumansIn patientGanciclovirLeukemiabusiness.industryHematopoietic Stem Cell TransplantationMaribavirmedicine.diseaseTransplantationClinical trialHaematopoiesisInfectious DiseasesHematologic NeoplasmsCytomegalovirus InfectionsPractice Guidelines as TopicBenzimidazolesRibonucleosidesStem cellbusinessmedicine.drugThe Lancet. Infectious diseases
researchProduct

Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutane…

2014

Background Histopathological diagnosis including selection of lesions, the determination of the best point of time for biopsy and workup is not trivial in cutaneous graft-versus-host disease (GvHD). Objectives To develop interdisciplinary recommendations on performing, the laboratory work up and reporting of the results of skin biopsies in patients with suspected cutaneous GvHD. Methods A working group consisting of dermatopathologists, dermatologists, transplant-physicians and transplant-pathologists prepared recommendations for performing skin biopsies, laboratory workup and evaluation of tissue samples, and reporting of the results in patients with cutaneous GvHD. After achieving a conse…

medicine.medical_specialtyConsensusBiopsymedicine.medical_treatmentMedizinGraft vs Host DiseaseDermatologyDiseaseSkin Diseasesimmune system diseasesSurveys and QuestionnairesBiopsyHumansTransplantation HomologousMedicineIn patientSkinintegumentary systemmedicine.diagnostic_testbusiness.industryHistological TechniquesHematopoietic Stem Cell TransplantationImmunosuppressionCutaneous graft-versus-host diseaseDermatologyWork-upSurgeryTransplantationsurgical procedures operativeInfectious DiseasesAcute DiseaseChronic DiseaseSkin biopsybusiness
researchProduct

Queratitis bacteriana por Moraxella nonliquefaciens

2020

Moraxella keratitis can lead to important complications. Moraxella nonliquefaciens(M. nonliquefaciens) has the worst prognosis. Only three cases of corneal infections due to M. nonliquefaciens have been published. The case is presented of a 79-year-old man with bullous keratopathy, recently affected with severe infectious keratitis. Dense, deep, and central stromal infiltrates and hyphaema were detected. After the identification of M. nonliquefaciens in the culture, and given the progression of the condition, the initial empirical treatment was modified to topical ciprofloxacin and ceftazidime in accordance with the antibiogram, combining oral ciprofloxacin and amoxicillin-clavulanate. Afte…

medicine.medical_specialtyCorneal Infectionbiologybusiness.industryInfectious Keratitismedicine.diseasebiology.organism_classificationDermatologyMoraxella nonliquefaciensKeratitisCiprofloxacinOphthalmologyLeucomamedicineBullous keratopathybusinessMoraxellamedicine.drugArchivos de la Sociedad Española de Oftalmología
researchProduct

Thoracic Anesthesia during the 2019 Novel Coronavirus Infection Pandemic: 2021 Updated Recommendations for Airway Management by the EACTAIC Thoracic …

2021

Contains fulltext : 244115.pdf (Publisher’s version ) (Closed access) The novel coronavirus pandemic has radically changed the landscape of normal surgical practice. Lifesaving cancer surgery, however, remains a clinical priority, and there is an increasing need to fully define the optimal oncologic management of patients with varying stages of lung cancer, allowing prioritization of which thoracic procedures should be performed in the current era. Healthcare providers and managers should not ignore the risk of a bimodal peak of mortality in patients with lung cancer; an imminent spike due to mortality from acute coronavirus disease 2019 (COVID-19) infection, and a secondary peak reflecting…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Critical Caremedicine.medical_treatmentcoronavirusThoracic anesthesiaSubspecialtyHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Special ArticleAnesthesiologyAnesthesiologyIntensive carePandemicmedicineHumansAnesthesiaLung cancerPandemicsbusiness.industrySARS-CoV-2COVID-19medicine.diseaseInfectious periodAnesthesiology and Pain MedicineAnesthesialung separationpersonal protective equipmentAirway managementCardiology and Cardiovascular MedicinebusinessJournal of Cardiothoracic and Vascular Anesthesia
researchProduct

COVID-19 Vaccine: A Survey of Hesitancy in Patients with Celiac Disease

2021

(1) Background: COVID-19 vaccination campaigns offer the best hope of controlling the pandemic. However, the fast production of COVID-19 vaccines has caused concern among the general public regarding their safety and efficacy. In particular, patients with chronic illnesses, such as celiac disease (CD), may be more fearful. Information on vaccine hesitancy plays a pivotal role in the development of an efficient vaccination campaign. In our study, we aimed to evaluate COVID-19 vaccine hesitancy among Italian CD patients. (2) Methods: an anonymous questionnaire was sent to CD patients followed at our tertiary referral center for CD in Milan, Italy. Patients were defined as willing, hesitant an…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)ImmunologyCOVID-19 vaccinesDiseaseArticle03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoveryPandemicMedicinePharmacology (medical)Adverse effectPharmacologyResponse rate (survey)business.industryRCOVID-19Odds ratiovaccinesConfidence intervalVaccinationInfectious Diseases030220 oncology & carcinogenesisMedicinevaccine hesitancy030211 gastroenterology & hepatologybusinessCOVID-19 vaccineceliac diseaseVaccines
researchProduct

COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNI…

2020

International audience; Introduction - Patients treated for malignancy are considered at risk of severe COVID-19. This exceptional pandemic has affected countries on every level, particularly health systems which are experiencing saturation. Like many countries, France is currently greatly exposed, and a complete reorganization of hospitals is ongoing. We propose here adaptations of diagnostic procedures, therapies and care strategies for patients treated for digestive cancer during the COVID-19 epidemic. Methods - French societies of gastroenterology and gastrointestinal (GI) oncology carried out this study to answer two main questions that have arisen (i) how can we limit high-risk situat…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia ViralDigestive cancerMEDLINEAntineoplastic AgentsFrench Clinical Practice Guidelines[SDV.CAN]Life Sciences [q-bio]/CancerComorbidityMalignancyBetacoronavirus03 medical and health sciences0302 clinical medicineHealth carePandemicDisease Transmission InfectiousHumansChemotherapyMedicineInfection controlIntensive care medicinePandemicsDigestive System Surgical ProceduresSocieties MedicalGastrointestinal NeoplasmsInfection ControlHepatologySARS-CoV-2business.industryGastroenterologyCOVID-19Evidence-based medicinemedicine.diseaseComorbidityPatient Care ManagementCOVID-19 infection3. Good health030220 oncology & carcinogenesisSurgery030211 gastroenterology & hepatologyFranceCoronavirus InfectionsbusinessDigestive and Liver Disease
researchProduct